Positive Psychological Deconditioning of Pediatric Patients With Dental Anxiety Through Artificial Intelligence
Launched by UNIVERSITY OF PAVIA · Feb 23, 2024
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
The World Health Organization classifies dental phobia as a disease, making it a significant concern in the field of dentistry and a considerable challenge for practitioners. It has been included in the International Classification of Diseases (ICD-10) as one of the specific phobias. According to WHO estimates, it affects 15-20% of the population. Notably, it is estimated that over 50% of pediatric patients may exhibit varying degrees of anxiety during dental treatments. Therefore, it is desirable to develop methods to address this issue.
Existing literature already contains studies using ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age between 5 and 10 years
- • Modified Dental Anxiety Scale (MDAS) (Humphris GM et al. 1995) greater than or equal to children must score equal to or higher than 19 in the questionnaire based on the "The modified dental anxiety scale."
- • FLACC score (Merkel, S. I. et al., 1997) greater than or equal to 4
- • Simplified Oral Hygiene Index (OHI-S) (Greene JC et al, 1964) greater than or equal to 1.3.
- Exclusion Criteria:
- • Previous Traumatic Dental/Orthodontic Treatments
- • Previous Hospitalizations
- • Intellectual Disabilities and Psychiatric Disorders
About University Of Pavia
The University of Pavia, a prestigious institution renowned for its commitment to academic excellence and research innovation, serves as a prominent clinical trial sponsor. With a strong emphasis on advancing medical knowledge and improving patient care, the university leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical research. Collaborating with leading healthcare professionals and institutions, the University of Pavia is dedicated to exploring novel therapeutic approaches and fostering the translation of scientific discoveries into clinical practice, ultimately aiming to enhance health outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pavia, Lombardy, Italy
Patients applied
Trial Officials
Andrea Scribante, DDS, MSc, PhD
Principal Investigator
Study Principal Investigator
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported